China’s biopharma sector enters the New Year on a high
A wave of lucrative licensing deals, drug approvals and positive policy moves spurred a pharmaceutical rally in 2025, but bigger biotechs are seeing more of the benefits Key Takeaways: The…
Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
The small nucleic acid drugs developer has positioned itself as a leader in siRNA therapeutics, boasting one of the world’s largest pipelines of drugs using the technology Key Takeaways: Ribo…
Low margins, losses dog Ringpai as it eyes Hong Kong IPO
The company hopes to become Hong Kong’s first publicly listed pet hospital chain, hoping investors will overlook its weak performance metrics Key Takeaways: Ringpai has filed to list in Hong…
Geneplus locks onto targeted medicine for IPO pitch
After a post-Covid earnings dip, the company is seeking a stable future as a provider of data and diagnostics for precision medicine and disease prevention Key Takeaways: The company’s…
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways: With the drug still…
Sainte Nutritional ladles up sinking business in renewed IPO application
The special-purpose formula maker’s net profit rose in the first half of this year, but the gains were due to factors unrelated to its core business Key Takeaways: Sainte Nutritional…
3SBio gears up for drugs battle with $400 million equity move
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio…
Recent Articles
RELATED ARTICLES
-
WORK Medical enters strategic partnerships in bid to explore RWA initiatives
WOK.US - Ming Yu seeks a share of the drug sector limelight
-
CSPC feels the pain from sweeping cuts in drug prices
1093.HK
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
-
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
-
XtalPi scores landmark deal for AI drug discovery
2228.HK
- Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
